Toes RE - Search Results

1

Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.

Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Wang J, et al. Among authors: toes re. Eur J Immunol. 2007 Jan;37(1):129-38. doi: 10.1002/eji.200636435. Eur J Immunol. 2007. PMID: 17154262

2

A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation.

Ossevoort MA, Toes RE, De Bruijn ML, Melief CJ, Figdor CG, Kast WM. Ossevoort MA, et al. Among authors: toes re. J Immunol Methods. 1992 Oct 19;155(1):101-11. doi: 10.1016/0022-1759(92)90276-y. J Immunol Methods. 1992. PMID: 1328395

3

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. Toes RE, et al. J Immunol. 1995 Apr 1;154(7):3396-405. J Immunol. 1995. PMID: 7534797

4

The MHC expression of dendritic cells from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture.

Ossevoort MA, Toes RE, De Bruijn ML, Melief CJ, Figdor CG, Kast WM. Ossevoort MA, et al. Among authors: toes re. Adv Exp Med Biol. 1993;329:185-9. doi: 10.1007/978-1-4615-2930-9_31. Adv Exp Med Biol. 1993. PMID: 8379369 No abstract available.

5

Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization.

Feltkamp MC, Vierboom MP, Toes RE, Ossendorp F, ter Schegget J, Melief CJ, Kast WM. Feltkamp MC, et al. Among authors: toes re. Immunol Lett. 1995 Jul-Aug;47(1-2):1-8. doi: 10.1016/0165-2478(95)00052-7. Immunol Lett. 1995. PMID: 8537084

6

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Toes RE, et al. J Immunol. 1996 May 15;156(10):3911-8. J Immunol. 1996. PMID: 8621930

7

Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.

Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Toes RE, et al. Cancer Res. 1996 Aug 15;56(16):3782-7. Cancer Res. 1996. PMID: 8706024

8

Peptide-based cancer vaccines.

Melief CJ, Offringa R, Toes RE, Kast WM. Melief CJ, et al. Among authors: toes re. Curr Opin Immunol. 1996 Oct;8(5):651-7. doi: 10.1016/s0952-7915(96)80081-1. Curr Opin Immunol. 1996. PMID: 8902390 Review.

9

Activation or frustration of anti-tumor responses by T-cell-based immune modulation.

Toes RE, Schoenberger SP, van der Voort EI, Kast WM, Hoeben RC, Melief CJ, Offringa R. Toes RE, et al. Semin Immunol. 1997 Oct;9(5):323-7. doi: 10.1006/smim.1997.0088. Semin Immunol. 1997. PMID: 9327527 Review.

10

Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion.

Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Melief CJ, Offringa R. Toes RE, et al. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14660-5. doi: 10.1073/pnas.94.26.14660. Proc Natl Acad Sci U S A. 1997. PMID: 9405669 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results